Microcap Biotech With Clinical and Global Tailwinds

This microcap is starting to appear on more watchlists. The US 2k-patient colorectal study is ongoing, while pancreatic cancer testing shows early accuracy of 100% sensitivity and 95% specificity.

They’ve raised $6M, regained Nasdaq compliance, and continue European expansion with lab partnerships, giving MYNZ the runway to hit multiple 2026 catalysts. Traders like the combination of low float and news-driven potential even minor headlines can move this stock 20-30% intraday.

On a global scale, early detection testing is projected to hit tens of billions over the next decade, and new research from NIH and EU labs confirms the growing adoption of blood-based, AI-assisted biomarker screening. This provides a strong macro tailwind for companies in this space. Bonus: add in 3 US-based partnerships which will boost expansion.

With so many upcoming catalysts, what do you think could be the first headline to push this stock higher? Not financial advice.